LawrenceHao-WenLuMD

Research • South San Francisco, CA

Oncology Clinical Development (Industry)

Join to view full profile

Dr. Lu is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Lu's full profile

Already have an account?

Office
121 Oyster Point Blvd
South San Francisco, CA 94080
Is this information wrong?

Education & Training

University of ColoradoFellowship, Nephrology, 2006 - 2009
University of ColoradoResidency, Internal Medicine, 2003 - 2006
Johns Hopkins University School of MedicineClass of 2003

Certifications & Licensure

CA State Medical License 2008 - 2020
NV State Medical License 2010 - 2015

Clinical Trials

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors Start of enrollment: 2019 Nov 20
Terminated
Phase 2
PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL Start of enrollment: 2018 Jun 15
Completed
Phase 1, Phase 2
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Start of enrollment: 2020 Jun 30
Terminated
Phase 3
A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors Start of enrollment: 2022 Feb 22
Recruiting
Phase 1
A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma Start of enrollment: 2017 Nov 16
Active, not recruiting
Phase 3
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma Start of enrollment: 2014 Oct 15
Completed
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

15 citations
CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding...
Rachel E. Sanborn, Omid Hamid, Elisabeth G.E. de Vries, Patrick A. Ott, Javier Garcia-Corbacho, Valentina Boni, Johanna C. Bendell, Karen A. Autio, Daniel C. Cho, Ruth...> ;Journal for Immunotherapy of Cancer. 2021 Jul 1
44 citations
Depletion of macrophages and dendritic cells in ischemic acute kidney injury.
Lawrence Lu, Sarah Faubel, Zhibin He, Ana Andres Hernando, Alkesh Jani, Ross M. Kedl, Charles L. Edelstein> ;American Journal of Nephrology. 2012 Jan 25
15 citations
Macrophages are not the source of injurious interleukin-18 in ischemic acute kidney injury in mice
Zhibin He, Belda Dursun, Dong-Jin Oh, Lawrence Lu, Sarah Faubel, Charles L. Edelstein> ;American Journal of Physiology. Renal Physiology. 2009 Jan 7
58 citations
Interleukin-18 binding protein transgenic mice are protected against ischemic acute kidney injury
Zhibin He, Lawrence Lu, Christopher Altmann, Thomas S. Hoke, Danica Galešić Ljubanović, Alkesh Jani, Charles A. Dinarello, Sarah Faubel, Charles L. Edelstein> ;American Journal of Physiology. Renal Physiology. 2008 Aug 27
110 citations
Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice
Dong-Jin Oh, Belda Dursun, Zhibin He, Lawrence Lu, Thomas S. Hoke, Danica Galešić Ljubanović, Sarah Faubel, Charles L. Edelstein> ;American Journal of Physiology. Renal Physiology. 2008 Jan 1
81 citations
Increased Macrophage Infiltration and Fractalkine Expression in Cisplatin-Induced Acute Renal Failure in Mice
Lawrence H. Lu, Dong-Jin Oh, Belda Dursun, Zhibin He, Thomas S. Hoke, Sarah Faubel, Charles L. Edelstein> ;The Journal of Pharmacology and Experimental Therapeutics. 2008 Jan 1
318 citations
Cisplatin-Induced Acute Renal Failure Is Associated with an Increase in the Cytokines Interleukin (IL)-1β, IL-18, IL-6, and Neutrophil Infiltration in the Kidney
Sarah Faubel, Eli C. Lewis, Leonid L. Reznikov, Danica Galešić Ljubanović, Thomas S. Hoke, Hilary Somerset, Dong-Jin Oh, Lawrence Lu, Christina L. Klein, Charles A. Di...> ;The Journal of Pharmacology and Experimental Therapeutics. 2007 Jul 1
Join now to see all

Grant Support

The Role Of Macrophages And Natural Killer Cells In Cisplatin-Induced Acute RenalNational Institute Of Diabetes And Digestive And Kidney Diseases2007

LawrenceHao-WenLuMD

Dr. Lu is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.